摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone | 203863-51-8

中文名称
——
中文别名
——
英文名称
5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone
英文别名
3,4-dihydroxy-2-[2-(4-phenylphenoxy)ethyl]-2H-furan-5-one
5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone化学式
CAS
203863-51-8
化学式
C18H16O5
mdl
——
分子量
312.322
InChiKey
OJUPHZIMIGLKOL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    554.3±50.0 °C(Predicted)
  • 密度:
    1.353±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    23
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    76
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    对羟基联苯3,4-bis(benzyloxy)-5-(2-hydroxyethyl)furan-2(5H)-one 以32%的产率得到5-[2-((1,1'-biphenyl)-4-oxy)ethyl]-3,4-dihydroxy-2(5H)-furanone
    参考文献:
    名称:
    5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use
    摘要:
    本发明涉及用于合成旋光活性和消旋5,5-二取代-3,4-二羟基-2(5H)-呋喃酮;5-[(4-芳基)-3-丁炔基]-3,4-二羟基-2(5H)-呋喃酮;5-(2-芳硫基)乙基-3,4-二羟基-2(5H)-呋喃酮;以及5-(2-芳氧基)乙基-3,4-二羟基-2(5H)-呋喃酮的生产的合成方法。本发明进一步涉及上述化合物作为抗炎药物的用途,通过它们作为脂质过氧化、5-脂氧合酶、环氧合酶-1和环氧合酶-2的混合抑制剂的作用。该发明还涉及将这些化合物用于治疗慢性炎症性疾病,如哮喘、类风湿性关节炎、炎症性肠病、动脉粥样硬化、急性呼吸窘迫综合征,以及阿尔茨海默病和帕金森病等中枢神经系统疾病,其中活性氧自由基和炎症介质是造成有害因素的。
    公开号:
    US06005000A1
点击查看最新优质反应信息

文献信息

  • Method for resolving racemic mixtures of 5-substituted 4-hydroxy-2-furanones
    申请人:——
    公开号:US20030065196A1
    公开(公告)日:2003-04-03
    This invention affords a solution to the technical problem of obtaining one or both enantiomers of 5-substituted 4-hydroxyfuran-2-ones in pure form by resolution with enantiomerically pure bases. Racemic mixtures of 5-substituted 4-hydroxy-2(5H)-furanones, including 5-substituted and 5,5-disubstituted, 4-hydroxy and 3,4-dihydroxy furanones are separated into pure enantiomers by crystallization with an enantiomerically pure base, such as cinchonidine. In specific solvent mixtures, for example, 95% ethanol, the diastereomerically pure salt of one enantiomer crystallizes. The enantiomerically pure furanone can then be obtained simply by filtration and treatment of the salt with an acid, for example, trifluoracetic acid, followed by precipitation with water, filtration and drying. Moreover, the other enantiomer may be equally obtained in pure form by evaporation of the mother liquor, followed by the same treatment of the salt as described before.
    本发明提供了一种解决技术问题的方法,即通过与对映纯基团分离得到5-取代4-羟基呋喃-2-酮的一个或两个对映体。包括5-取代和5,5-二取代,4-羟基和3,4-二羟基呋喃酮的混合物被晶化与对映纯碱,例如金鸡纳碱,分离成纯对映体。在特定的溶剂混合物中,例如95%的乙醇,一个对映异构体纯盐结晶。然后可以通过过滤和用酸处理盐,例如三氟乙酸,随后用水沉淀,过滤和干燥来获得对映纯呋喃酮。此外,通过蒸发母液,然后用与之前相同的方法处理盐,同样可以获得另一个对映体的纯形式。
  • Pharmaceutical methods of use of 5-substituted and 5,5 disubstituted-3,4-dihydroxy-2(5H)-furanones
    申请人:Oxis International Inc.
    公开号:US06262073B1
    公开(公告)日:2001-07-17
    The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.
    本发明涉及合成方法,用于生产旋光和消旋5,5-二取代-3,4-二羟基-2(5H)-呋喃酮;5-[(4-芳基)-3-丁炔基]-3,4-二羟基-2(5H)-呋喃酮;5-(2-芳硫基)乙基-3,4-二羟基-2(5H)-呋喃酮;以及5-(2-芳氧基)乙基-3,4-二羟基-2(5H)-呋喃酮。本发明进一步涉及上述化合物的用途,作为抗炎剂,通过它们作为脂质过氧化、5-脂氧合酶、环氧化酶-1和环氧化酶-2的混合抑制剂的作用。本发明进一步涉及在治疗慢性炎症性疾病,如哮喘、类风湿性关节炎、炎症性肠病、动脉粥样硬化、急性呼吸窘迫综合征和中枢神经系统疾病,如阿尔茨海默病和帕金森病中使用这些化合物,其中活性氧物质和炎症介质是造成有害因素的贡献者。
  • 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones and methods of use
    申请人:Oxis International Inc.
    公开号:US06136832A1
    公开(公告)日:2000-10-24
    The present invention relates to synthetic methods for the production of both optically active and racemic 5,5-disubstituted-3,4-dihydroxy-2(5H)-furanones; 5-[(4-aryl)-3-butynyl]-3,4-dihydroxy-2(5H)-furanones; 5-(2-arylthio)ethyl-3,4-dihydroxy-2(5H)-furanones; and 5-(2-aryloxy)ethyl-3,4-dihydroxy-2(5H)-furanones. This invention further relates to the use of the above mentioned compounds as anti-inflammatory agents through their action as mixed inhibitors of lipid peroxidation, 5-lipoxygenase, cyclooxygenase-1 and cyclooxygenase-2. The invention further relates to the use of such compounds in the treatment of chronic inflammatory disorders such as asthma, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, acute respiratory distress syndrome, and central nervous system disorders such as Alzheimer's and Parkinson's disease wherein reactive oxygen species and inflammatory mediators are contributing deleterious factors.
    本发明涉及合成方法,用于生产旋光和消旋5,5-二取代-3,4-二羟基-2(5H)-呋喃酮;5-[(4-芳基)-3-丁炔基]-3,4-二羟基-2(5H)-呋喃酮;5-(2-芳硫基)乙基-3,4-二羟基-2(5H)-呋喃酮;以及5-(2-芳氧基)乙基-3,4-二羟基-2(5H)-呋喃酮。本发明还涉及上述化合物作为抗炎药物的用途,通过它们作为脂质过氧化、5-脂氧合酶、环氧合酶-1和环氧合酶-2的混合抑制剂的作用。本发明还涉及在治疗慢性炎症性疾病,如哮喘、类风湿性关节炎、炎症性肠病、动脉粥样硬化、急性呼吸窘迫综合征以及中枢神经系统疾病,如阿尔茨海默病和帕金森病等,其中活性氧和炎症介质是致病因素的情况下使用这些化合物的用途。
  • 5-SUBSTITUTED AND 5,5-DISUBSTITUTED-3,4-DIHYDROXY-2(5H)-FURANONES AND METHODS OF USE THEREFOR
    申请人:Oxis International, Inc.
    公开号:EP0938482A1
    公开(公告)日:1999-09-01
  • METHODS FOR RESOLVING RACEMIC MIXTURES OF 5-SUBSTITUTED 4-HYDROXY-2-FURANONES
    申请人:OXIS Isle of Man, Limited
    公开号:EP1246811B1
    公开(公告)日:2003-12-03
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐